Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of High-grade Gliomas Using Escalating Doses of Hypofractionated Simultaneous Integrated Boost-intensity Modulated Radiation Therapy in Combination With Temozolomide - a Modified Phase I Clinical Trial

NCT03082846 is registered in ClinicalTrials.gov with Xue Xiaoying as lead sponsor.

NCT NCT03082846
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03082846 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of High-grade Gliomas Using Escalating Doses of Hypofractionated Simultaneous Integrated Boost-intensity Modulated Radiation Therapy in Combination With Temozolomide - a Modified Phase I Clinical Trial
Lead sponsor
Xue Xiaoying
Phase
Not applicable
Overall status
Completed
Start date
January 1, 2014
Completion date
December 3, 2016
Enrollment
16 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

glioma, maximum tolerated dose, radiotherapy, intensity-modulated